Syndax Pharmaceuticals Inc’s filing revealed that its Chief Financial Officer Goldan Keith A. acquired Company’s shares for reported $25037.0 on Jun 14 ’24. In the deal valued at $20.03 per share,1,250 shares were bought. As a result of this transaction, Goldan Keith A. now holds 52,623 shares worth roughly $0.85 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
UBS initiated its Syndax Pharmaceuticals Inc [SNDX] rating to a Buy in a research note published on October 24, 2024; the price target was $37. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Scotiabank also remained covering SNDX and has decreased its forecast on January 31, 2024 with a “Sector perform” recommendation from previously “Sector outperform” rating. Mizuho started covering the stock on December 22, 2023. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Monday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock jump 1.77% to $16.11. Over the last five days, the stock has lost -26.03%. Syndax Pharmaceuticals Inc shares have fallen nearly -25.45% since the year began. Nevertheless, the stocks have risen 8.78% over the past one year. While a 52-week high of $25.34 was reached on 02/28/24, a 52-week low of $14.50 was recorded on 11/15/24. SMA at 50 days reached $18.82, while 200 days put it at $20.88.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 15.59, which if violated will result in even more drops to 15.08. On the upside, there is a resistance level at 16.76. A further resistance level may holdings at 17.42. The Relative Strength Index (RSI) on the 14-day chart is 34.99, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.29%. Stochastics %K at 8.39% indicates the stock is a buying.
How much short interest is there in Syndax Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syndax Pharmaceuticals Inc stocks on 2024-10-31, growing by 0.58 million shares to a total of 10.66 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 10.08 million shares. There was a rise of 5.4%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 25, 2023 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $29 price target.
